Progranulin Deficiency Increases Vulnerability Of Human Neuroblastoma SH-SY5Y Cells To Serum Withdrawal-induced Apoptosis | 21979
Journal of Alzheimers Disease & Parkinsonism
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Null mutations in GRN are associated with frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP).
However the influence of progranulin (PGRN) deficiency on neurodegenation is largely unknown. In neuroblastoma
cells, silencing of GRN gene causes significantly reduced cell survival after serum withdrawal. It was observed that PGRN
deficient cells (KD GRN) are more vulnerable to serum deprivation than control cells. The supplementation of recombinant
human PGRN restored the survival of KD cells. The following observations suggest that modulation of the CDK6/pRb pathway
secondary to changes in the activity of the PI3K/Akt and ERK1/2 signaling pathways, induced by PGRN levels is involved in
the altered regulation of serum deprivation-induced apoptosis. (i) The specific CDK6 inhibitors, sodium butyrate or PD332991
sensitized control SH-S5Y5 cells to serum deprivation-induced apoptosis without affecting survival of PGRN deficient cells.
(ii) CDK6/pRb seems to be downstream of the PI3K/Aktand ERK1/2pathways since their specific inhibitor, Ly294002 and
PD98059 were able to decrease CDK6 activity and induced death of control SH-SY5Y cells. (iii) PGRN deficient cells show
reduced stimulation of Akt, ERK1/2, and CDK6-associated kinase activities than in control cells in the absence of serum. These
observations highlight the important role of PGRN-mediated stimulation of the PI3K/Akt/ERK1/2 and CDK6/pRb pathways
in determining the cell fate survival/death under serum deprivation.
Angeles Martin Requero is Doctor of Biological Sciences, Complutense University of Madrid in 1978. she completed Postdoctoral Fellow in University of
Pennsylvania, Philadelphia, USA in 1979-1982. She worked as as a Professor in University of Extremadura (1982-1983). Scientific Holder in 1985. In 1996-1997
she worked as a Visiting Scientist in Medical Scholl, University of California (UCLA), Los Angeles, USA. In 2008 she is a Research Scientist.she currently heads
the laboratory devoted to ?study the cellular and molecular basis of Alzheimer?s disease and other dementias, ? in the Department of Cellular and Molecular
Medicine, Center for Biological Research (CSIC). She has authored more than 50 publications in international journals and a hundred communications in national
and international conferences.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals